Accordingly, serum levels of IL-11, STAT3 and TGF-β were higher in patients with metastases to the bone compared with patients with only primary breast cancer, with the metastatic group showing associated poorer survival outcomes [55]. This evidence concerns the gene IL11 and breast carcinoma.